GSK launches 'More than Medicine' corporate blog

Share this article:
GlaxoSmithKline announced the launch of a corporate blog for the US, titled More than Medicine. The blog went live last January.

Topics covered so far range from healthcare policy news and GSK financial reports, to relieving stress and avoiding sunburn. According to a statement on the blog, its goal is to “encourage an open, productive discussion about a range of topics related to the US healthcare system and how it can be improved.”

Michael Fleming, senior director of social media at GSK, told PRWeek that GSK “would like people to hear from our company and interact with our company in…a less formal, less rigid way than they are used to hearing from us,” noting that the kind of dialogue featured on the blog is “not being offered by any other company.”

Several healthcare bloggers have already questioned More than Medicine's authorship – articles contain a first name but not a last name – leading to a post on Thursday titled “Content is King Here, Not the One Who Posts It." The author, Michael F – most likely Michael Fleming – wrote in the post that “legitimate privacy and security concerns” limit the amount of personal information the authors can provide externally. “One of us has already been quoted in the press about this blog, so we're certainly not hiding anything; but the larger point is that this blog is not about any of us individually; it is about the company as a whole,” wrote Michael F.

Marc Monseau, the editor of Johnson & Johnson's corporate blog JNJ BTW, commended GSK on the launch in a comment on More than Medicine, and reiterated the need for a “candid, constructive dialogue” about how pharmaceutical companies “can be part of the conversation about health and healthcare issues on the social web.”
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.